Brussels - Delayed Quote EUR

UCB SA (UCB.BR)

281.40 +1.40 (+0.50%)

At close: October 30 at 5:35:29 PM GMT+1

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

UCB S.A. Digital Transformation Strategy Analysis Report 2025: Accelerators, Innovation Programs, Technology Initiatives, ICT, Partnerships, Investments & Acquisitions, Network Map

GlobeNewswire 6mo ago

UCB.BR
+0.50%
UCB (UCBJY) Upgraded to Strong Buy: Here's What You Should Know

Zacks 6mo ago

UCB.BR
+0.50%
UCBJF

UCBJY
UCB (ENXTBR:UCB) Raises 2026 Guidance After Strong BIMZELX And CIMZIA Demand

Simply Wall St. 7d ago

UCB.BR
+0.50%
Is UCB (ENXTBR:UCB) Undervalued As It Expands Its Biologics Campus In Georgia?

Simply Wall St. 21d ago

UCB.BR
+0.50%
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

GlobeNewswire 4mo ago

BIIB

UCB.BR
+0.50%
Is It Too Late To Consider UCB (ENXTBR:UCB) After A 195% Three Year Surge?

Simply Wall St. 6mo ago

UCB.BR
+0.50%
A Look At UCB (ENXTBR:UCB) Valuation After Neurology Conference Data And Real World Results

Simply Wall St. 6mo ago

UCB.BR
+0.50%
UCB (UCBJY) Upgraded to Buy: Here's Why

Zacks 1mo ago

UCBJF
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

Zacks 1mo ago

UCBJY

ALPMY

ONC
UCB SA (UCBJF) (H1 2026) Earnings Call Highlights: Record Sales and Strategic Expansion Drive ...

GuruFocus.com 2mo ago

UCB.BR
+0.50%
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

GlobeNewswire 4mo ago

BIIB

UCB.BR
+0.50%
UCB - Convening Notice to the General Meeting of the Shareholders 2026

GlobeNewswire 7mo ago

UCB.BR
+0.50%

Performance Overview

Return	UCB.BR	BEL 20 (^BFX)
YTD	+19.43%	+15.03%
1-Year	+20.35%	+17.47%
3-Year	+317.29%	+77.50%

U.S. markets closed

UCB SA (UCB.BR)

UCB S.A. Digital Transformation Strategy Analysis Report 2025: Accelerators, Innovation Programs, Technology Initiatives, ICT, Partnerships, Investments & Acquisitions, Network Map

UCB (UCBJY) Upgraded to Strong Buy: Here's What You Should Know

UCB (ENXTBR:UCB) Raises 2026 Guidance After Strong BIMZELX And CIMZIA Demand

Is UCB (ENXTBR:UCB) Undervalued As It Expands Its Biologics Campus In Georgia?

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Is It Too Late To Consider UCB (ENXTBR:UCB) After A 195% Three Year Surge?

A Look At UCB (ENXTBR:UCB) Valuation After Neurology Conference Data And Real World Results

UCB (UCBJY) Upgraded to Buy: Here's Why

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

UCB SA (UCBJF) (H1 2026) Earnings Call Highlights: Record Sales and Strategic Expansion Drive ...

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

UCB - Convening Notice to the General Meeting of the Shareholders 2026